@Article{,
AUTHOR = {Andrew Salib, J. Ryan Mark},
TITLE = {DNA analysis for prostate specimen verification: How I Do It},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {28},
YEAR = {2021},
NUMBER = {1},
PAGES = {10568--10573},
URL = {http://www.techscience.com/CJU/v28n1/60238},
ISSN = {1488-5581},
ABSTRACT = {Prostate cancer is the most common malignancy affecting 
men. Prostate biopsy remains the key clinical tool for 
selecting appropriate treatment options. The process 
of specimen collection and diagnosis is multistep and 
vulnerable to human error along every stage. Specimen 
provenance testing (SPT) aims to provide certainty that 
biopsy results can be trusted when recommending life 
changing treatments and has emerged as a necessary 
tool in medicine to counteract human error and specimen 
contamination. In this study we report our practice’s 
experience using the Know Error test to verify prostate 
biopsy specimens. In this study, we retrospectively 
reviewed the results of a specific SPT known as Know 
Error which is used in our institution for specimen verification during prostate biopsy. Over a period of 
16 months, we identified 445 patients with a total of 
921 specimens. The percentage of patients who had 1, 
2 or 3 specimens analyzed was 29%, 38%, and 30%, 
respectively. Our cohort’s rate of specimen verification 
was 92.8% with a 2.8% contamination rate. The 
pathology reports for 445 patients were then examined 
to determine Gleason Grade Group (GG) showing 180 
GG1 and 148 GG2 patients. Cross reference of pathology 
reports and Know Error reports showed 8 GG1 and 9 GG2 
patients had contaminated biopsy specimens. Specimen 
provenance complications such as contamination can 
negatively impact patient counselling and treatment 
modalities leading to unnecessary intervention and 
detrimental patient outcomes.},
DOI = {}
}